Evidence map›Paper›PMID 33422094›Full record

ArticleMolecular cytogenetics2021

Patient-friendly integrated first trimester screening by NIPT and fetal anomaly scan.

Malgorzata Ilona Srebniak, Maarten F C M Knapen, Marieke Joosten, Karin E M Diderich, Sander Galjaard, Diane Van Opstal

Open access · goldAbstract read
In one paragraph

Article in Molecular cytogenetics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.3field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Malgorzata Ilona SrebniakDepartment of Clinical Genetics, Erasmus MC, Wytemaweg 80, 3015 CN, Rotterdam, The Netherlands. m.srebniak@erasmusmc.nl.ORCID http://orcid.org/0000-0003-3429-6156
Maarten F C M KnapenDepartment of Obstetrics and Fetal Medicine, Erasmus MC, Rotterdam, The Netherlands.
Marieke JoostenDepartment of Clinical Genetics, Erasmus MC, Wytemaweg 80, 3015 CN, Rotterdam, The Netherlands.
Karin E M DiderichDepartment of Clinical Genetics, Erasmus MC, Wytemaweg 80, 3015 CN, Rotterdam, The Netherlands.
Sander GaljaardDepartment of Obstetrics and Fetal Medicine, Erasmus MC, Rotterdam, The Netherlands.
Diane Van OpstalDepartment of Clinical Genetics, Erasmus MC, Wytemaweg 80, 3015 CN, Rotterdam, The Netherlands.
Erasmus MC · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Many major structural fetal anomalies can be diagnosed by first trimester fetal anomaly scan. NIPT can accurately detect aneuploidies and large chromosomal aberrations in cfDNA in maternal blood plasma. This study shows how a patient-friendly first trimester screening for both chromosomal and structural fetal anomalies in only two outpatient visits can be provided. Genotype-first approach assures not only the earliest diagnosis of trisomy 21 (the most prevalent chromosome aberration), but also completion of the screening at 12-14 weeks. To ensure proper management and avoid unnecessary anxiety abnormal NIPT different from trisomy 21, 18 and 13 should be referred for genetic counseling.

Indexed as

Fetal anomaly scanFirst trimesterNIPTPrenatal screening

Identifiers

PMID33422094
PMCPMC7797124
OpenAlexW3120499722

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.